QCG
FRTX

Quadrant Capital Group’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Quadrant Capital Group’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-400
Closed -$20K – 2615
2021
Q1 		$20K Buy
+400
New +$22K ﹤0.01% 1187

Other funds holding FRTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSWM
Smith Salley Wealth Management Greensboro, North Carolina $2.3B AUM 38.65% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Quadrant Capital Group's FRTX Position: Q2 2021 in Review

Quadrant Capital Group sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q2 2021, closing a stake of 400 shares — an estimated $20K sold.

Quadrant Capital Group first reported a position in FRTX in Q1 2021 and held it in 1 quarter. The position peaked at $20K in Q1 2021. 30 funds tracked by Wall St. Rank hold FRTX as of Q2 2021.

  • Quadrant Capital Group reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Quadrant Capital Group sold 400 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $20K.
  • Quadrant Capital Group first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Quadrant Capital Group's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $20K in Q1 2021.
  • 30 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Quadrant Capital Group's 13F filing for Q2 2021, filed 9 Aug 2021.